Takeda Pharmaceutical Projects Lower Annual Profit After Quarterly Loss
By Kosaku Narioka
Takeda Pharmaceutical reported a fourth-quarter loss and forecast a drop in annual net profit due partly to restructuring expenses.
The Japanese drugmaker said Thursday that it booked a net loss of 3.0 billion yen ($19.3 million) for the three months ended March, compared with a net profit of Y31.1 billion a year earlier.
Fourth-quarter revenue increased 9.9% to Y1.051 trillion.
For the year that began in April, it projected net profit to drop 60% to Y58.00 billion and revenue to increase 2.0% to Y4.350 trillion.
Takeda said it expects to book Y140.0 billion in restructuring expenses this fiscal year under a new initiative aiming for growth and cost cuts.
Write to Kosaku Narioka at kosaku.narioka@wsj.com
(END) Dow Jones Newswires
May 09, 2024 03:08 ET (07:08 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Markets Brief: Tech Stocks Lead Ahead of Nvidia Earnings
-
How Anti-Obesity Drugs Are Innovating the Healthcare Market
-
What’s Happening In the Markets This Week
-
Why Immigration Has Boosted Job Gains and the Economy
-
What to Invest in During High Inflation
-
Never Mind Market Efficiency: Are the Markets Sensible?
-
Starbucks Stock Could Use a Pick-Me-Up After Big Selloff; Is it a Buy?
-
5 Cheap Stocks to Buy From an Attractive Part of the Market
-
After Earnings, Is Lyft Stock a Buy, a Sell, or Fairly Valued?
-
8 Stock Picks in the Apparel Industry
-
Baidu Earnings: Advertising Weakness Offset by Continued Growth In Cloud Business
-
Going Into Earnings, Is Target Stock a Buy, a Sell, or Fairly Valued?
-
Walmart Earnings: Low Prices and Strong Digital Presence Drive Market Share Gains
-
After Earnings and a Big Selloff, Is Shopify Stock a Buy, a Sell, or Fairly Valued?
-
Cisco Earnings: Positive Guidance and Splunk Inclusion Align With Our Long-Term Thesis
-
3 Warren Buffett Stocks to Buy After Berkshire Hathaway’s Just-Released 13F Filing